Study Phase 3

A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy

Trial Information

Generic NameCanagliflozinProduct NameINVOKANA®Therapeutic AreaNutritional and Metabolic DiseasesEnrollment4401% Female33.9%% White40.7%
Product ClassSodium-Glucose Co-Transporter 2 (SGLT2) InhibitorSponsor Protocol Number28431754DNE3001Data PartnerJohnson & JohnsonCondition StudiedDiabetes Mellitus, Type 2Mean/Median Age (Years)63

Supporting Documentation

  • Collected Datasets Available
  • Data Definition Specification Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Approved Data Requests Associated with this Trial

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.